Permanent Interstitial Brachytherapy for Prostate Cancer: a Current Review

Overview

Journal World J Urol

Specialty Urology

Date 2003 Aug 16

PMID 12920559

Citations 2

Authors

Jeffrey Woolsey

Nicole Miller

Dan Theodorescu

Affiliations

Soon will be listed here.

Abstract

Prostate brachytherapy with permanent radioactive implants is becoming an increasingly popular treatment choice for patients with prostate cancer. This therapy is attractive to patients due to the fact that it is an outpatient procedure and in many cases has been associated with lower long-term risks of urinary incontinence and erectile dysfunction when compared to other curative modalities. This review will describe the history, isotopes used, implantation techniques, and results achieved with modern prostate brachytherapy. Results will be discussed both in terms of cancer control and health-related quality of life endpoints.

Citing Articles

Brachytherapy using injectable seeds that are self-assembled from genetically encoded polypeptides in situ.

Liu W, McDaniel J, Li X, Asai D, Quiroz F, Schaal J Cancer Res. 2012; 72(22):5956-65.

PMID: 23155121 PMC: 3502020. DOI: 10.1158/0008-5472.CAN-12-2127.

Erectile dysfunction following radiotherapy and brachytherapy for prostate cancer: pathophysiology, prevention and treatment.

Akbal C, Tinay I, Simsek F, Turkeri L Int Urol Nephrol. 2007; 40(2):355-63.

PMID: 17960489 DOI: 10.1007/s11255-007-9247-1.

References

Zelefsky M, Hollister T, Raben A, Matthews S, Wallner K . Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2000; 47(5):1261-6. DOI: 10.1016/s0360-3016(00)00550-2. View

RAGDE H, Blasko J, Grimm P, Kenny G, Sylvester J, Hoak D . Brachytherapy for clinically localized prostate cancer: results at 7- and 8-year follow-up. Semin Surg Oncol. 1997; 13(6):438-43. DOI: 10.1002/(sici)1098-2388(199711/12)13:6<438::aid-ssu8>3.0.co;2-b. View

Ravery V . Brachytherapy versus radical prostatectomy. BJU Int. 2001; 87(2):141-3. DOI: 10.1046/j.1464-410x.2001.00026.x. View

Willins J, Wallner K . CT-based dosimetry for transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1997; 39(2):347-53. DOI: 10.1016/s0360-3016(97)00322-2. View

Vicini F, Vargas C, Edmundson G, Kestin L, Martinez A . The role of high-dose rate brachytherapy in locally advanced prostate cancer. Semin Radiat Oncol. 2003; 13(2):98-108. DOI: 10.1053/srao.2003.50009. View

Merrick G, Butler W, Dorsey A, Lief J, Donzella J . A comparison of radiation dose to the neurovascular bundles in men with and without prostate brachytherapy-induced erectile dysfunction. Int J Radiat Oncol Biol Phys. 2000; 48(4):1069-74. DOI: 10.1016/s0360-3016(00)00746-x. View

Zelefsky M, WHITMORE Jr W . Long-term results of retropubic permanent 125iodine implantation of the prostate for clinically localized prostatic cancer. J Urol. 1997; 158(1):23-9; discussion 29-30. DOI: 10.1097/00005392-199707000-00005. View

Hurwitz M, Cormack R, Tempany C, Kumar S, DAmico A . Three-dimensional real-time magnetic resonance-guided interstitial prostate brachytherapy optimizes radiation dose distribution resulting in a favorable acute side effect profile in patients with clinically localized prostate cancer. Tech Urol. 2000; 6(2):89-94. View

Merrick G, Butler W, Galbreath R, Stipetich R, Abel L, Lief J . Erectile function after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2002; 52(4):893-902. DOI: 10.1016/s0360-3016(01)02675-x. View

10.

Koutrouvelis P . Three-dimensional stereotactic posterior ischiorectal space computerized tomography guided brachytherapy of prostate cancer: a preliminary report. J Urol. 1997; 159(1):142-5. DOI: 10.1016/s0022-5347(01)64037-0. View

11.

Hall J, Boyd J, Lippert M, Theodorescu D . Why patients choose prostatectomy or brachytherapy for localized prostate cancer: results of a descriptive survey. Urology. 2003; 61(2):402-7. DOI: 10.1016/s0090-4295(02)02162-3. View

12.

Catalona W, RAMOS C, Carvalhal G . Contemporary results of anatomic radical prostatectomy. CA Cancer J Clin. 2001; 49(5):282-96. DOI: 10.3322/canjclin.49.5.282. View

13.

Elshaikh M, Angermeier K, Ulchaker J, Klein E, Chidel M, Mahoney S . Effect of anatomic, procedural, and dosimetric variables on urinary retention after permanent iodine-125 prostate brachytherapy. Urology. 2003; 61(1):152-5. DOI: 10.1016/s0090-4295(02)02142-8. View

14.

Ling C . Permanent implants using Au-198, Pd-103 and I-125: radiobiological considerations based on the linear quadratic model. Int J Radiat Oncol Biol Phys. 1992; 23(1):81-7. DOI: 10.1016/0360-3016(92)90546-t. View

15.

FLOCKS R, KERR H, ELKINS H, Culp D . The treatment of carcinoma of the prostate by interstitial radiation with radioactive gold (Au198); a follow-up report. J Urol. 1954; 71(5):628-33. DOI: 10.1016/S0022-5347(17)67835-2. View

16.

Gelblum D, Potters L, Ashley R, Waldbaum R, Wang X, Leibel S . Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys. 1999; 45(1):59-67. DOI: 10.1016/s0360-3016(99)00176-5. View

17.

Nag S, Beyer D, Friedland J, Grimm P, Nath R . American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 1999; 44(4):789-99. DOI: 10.1016/s0360-3016(99)00069-3. View

18.

Stock R, Kao J, Stone N . Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. J Urol. 2001; 165(2):436-9. DOI: 10.1097/00005392-200102000-00020. View

19.

Dibiase S, Wallner K, Tralins K, Sutlief S . Brachytherapy radiation doses to the neurovascular bundles. Int J Radiat Oncol Biol Phys. 2000; 46(5):1301-7. DOI: 10.1016/s0360-3016(99)00551-9. View

20.

Coblentz T, Bissonette E, Williams K, Theodorescu D . Multimodality radiotherapy and androgen ablation in the treatment of clinically localized prostate cancer: early results in high risk patients. Prostate Cancer Prostatic Dis. 2002; 5(3):219-25. DOI: 10.1038/sj.pcan.4500585. View